CGTX · Cognition Therapeutics Inc
Market Cap
$97.95M
Shares
95.09M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$23.49M
+30.9%
FY2025
Diluted EPS
-$0.32
+62.8%
FY2025
Operating Cash Flow
-$24.59M
+13.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| -$27K | — | — | -$27K | -$28K | -$893K | -$1.75M | |
| $26.14M | $37.19M | $41.68M | $37.2M | $30.32M | $18.57M | $12.89M | |
| $10.46M | $10.61M | $12.29M | $13.53M | $13.23M | $10.03M | $4.52M | |
| — | $36K | $107K | $96K | $83K | $93K | $98K | |
| $36.6M | $47.8M | $53.97M | $50.72M | $43.55M | $28.6M | $17.41M | |
| -$36.6M | -$47.8M | -$53.97M | -$50.72M | -$43.55M | -$28.6M | -$17.41M | |
| $19.83M | $24.31M | $20M | $24.94M | $22.15M | $16.88M | $9.57M | |
| — | $0 | $0 | $0 | $0 | $0 | — | |
| -$16.78M | -$23.49M | -$33.97M | -$25.79M | -$21.4M | -$11.72M | -$7.84M | |
| -$23.73M | — | — | — | -$21.4M | -$16.25M | -$12.07M | |
| -$16.78M | -$23.49M | -$33.78M | -$25.78M | -$21.4M | -$11.73M | -$7.84M | |
| USD/shares | -$0.16 | -$0.32 | -$0.86 | -$0.86 | -$0.91 | -$3.13 | -$23.76 |
| USD/shares | -$0.16 | -$0.32 | -$0.86 | -$0.86 | -$0.91 | -$3.13 | -$23.76 |
| shares | — | 72.77M | 39.73M | 30.03M | 23.64M | 5.19M | 508.11K |
| shares | — | 72.77M | 39.73M | 30.03M | 23.64M | 5.19M | 508.11K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 6.24×
EV/EBIT
—
Peer median 11.84×
P/E (TTM)
—
Peer median 8.64×
Peer medians compare against the 303 similar-size Biotechnology companies (of 537 listed).
Key facts
CIK
1455365
CUSIP
19243B102
13F (30d)
47 filings
47 filers
Visit website
Investor relations